ith the sponsor's initial NSR assessment and approves the study, the study may
begin without submission of an IDE application to FDA. If the IRB disagrees, the sponsor
should notify FDA that an SR determination has been made. The study can be conducted as an
SR investigation following FDA approval of an IDE application. </p>

<p>The risk determination should be based on the proposed use of a device in an
investigation, and not on the device alone. In deciding if a study poses an SR, an IRB
must consi